

-6-

Serial No.: 09/529,232

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

Claim 1. (currently amended) A thrombin inhibitor of formula (I) or a pharmaceutically acceptable salt thereof:




wherein

AS represents a S subsite blocking segment;

P represents a fibrinogen recognition exosite blocking segment; and

Z represents a S' subsite blocking segment which links AS and P, said S' subsite blocking segment having the following sequence:



wherein Xaa is a residue selected from the group of residue consisting of glycine, L-alanine, D-alanine, 2-aminoisobutyric acid, L- α -aminobutyric acid, D- α -aminobutyric acid, L-norvaline, D-norvaline, L-norleucine, D-norleucine, L-cysteine, L-penicillamine, D-penicillamine, L-methionine, D-methionine, L-valine, D-valine, L-tert-butylglycine, D-tert-butylglycine, L-isoleucine, D-isoleucine, L-leucine, D-leucine, cyclohexylglycine, L- β -cyclohexylalanine, D- β -cyclohexylalanine, L-phenylglycine, D-phenylglycine, L-phenylalanine, D-phenylalanine, L-homophenylalanine, D-homophenylalanine, L-histidine, D-histidine, L-tryptophan, D-tryptophan, L- β -(2-thienyl)-alanine, and D- β -(2-thienyl)-alanine;

Yaa is selected from the group of residue consisting of glycine, L-alanine, D-alanine, 2-aminoisobutyric acid, L- α -aminobutyric acid, D- α -aminobutyric acid, L-norvaline, D-norvaline, L-norleucine, D-norleucine, L-cysteine, L-penicillamine, D-penicillamine, L-methionine, D-methionine, L-valine, D-valine, L-tert-butylglycine, D-tert-butylglycine, L-isoleucine, D-isoleucine, L-leucine, D-leucine, cyclohexylglycine, L- β -cyclohexylalanine, D- β -cyclohexylalanine, L-phenylglycine, D-phenylglycine, L-phenylalanine, D-phenylalanine, homophenylalanine, histidine, L-tryptophan, D-tryptophan, L- β -(2-thienyl)-alanine, and D- β -(2-thienyl)-alanine.

Supprimé : n

-7-

Serial No.: 09/529,232

Claim 2. (currently amended) The thrombin inhibitor of claim 1, wherein AS has the following sequence:

Supprimé : A3

Bbs-Arg-(D-Pip),

wherein Bbs and D-Pip represent 4-tert-butylbenzenesulfonyl and D-pipecolic acid, respectively.

Claim 3. (currently amended) The thrombin inhibitor of claim 1, wherein P has the following sequence:

Asp-Tyr-Glu-Pro-Ile-Pro-Glu-Glu-Ala-Cha-(D-Glu)-OH,

wherein Cha represents β -cyclohexyl-alanine.

Claim 4. (currently amended) The thrombin inhibitor of claim 2, wherein P has the following sequence:

Asp-Tyr-Glu-Pro-Ile-Pro-Glu-Glu-Ala-Cha-(D-Glu)-OH,

wherein Cha represents β -cyclohexyl-alanine.

Claim 5. (currently amended) The inhibitor of claim 1, wherein said inhibitor is selected from the group consisting of:

Supprimé : compound

Supprimé : compound

- 1) Bbs-Arg-(D-Pip)-Gly-Gly-(D-Ala)-Gly- β Ala-Asp-Tyr-Glu-Pro-Ile-Pro-Glu-Glu-Ala-Cha-(D-Glu)-OH;
(SEQ ID NO:3)
- 2) Bbs-Arg-(D-Pip)- α Abu-Gly-Gly-Gly- β Ala-Asp-Tyr-Glu-Pro-Ile-Pro-Glu-Glu-Ala-Cha-(D-Glu)-OH;
(SEQ ID NO:3)
- 3) Bbs-Arg-(D-Pip)-Gly-Gly-(D- α Abu)-Gly- β Ala-Asp-Tyr-Glu-Pro-Ile-Pro-Glu-Glu-Ala-Cha-(D-Glu)-OH;
(SEQ ID NO:3)
- 4) Bbs-Arg-(D-Pip)-Nva-Gly-Gly-Gly- β Ala-Asp-Tyr-Glu-Pro-Ile-Pro-Glu-Glu-Ala-Cha-(D-Glu)-OH;
(SEQ ID NO:3)
- 5) Bbs-Arg-(D-Pip)-Gly-Gly-(D-Nva)-Gly- β Ala-Asp-Tyr-Glu-Pro-Ile-Pro-Glu-Glu-Ala-Cha-(D-Glu)-OH;
(SEQ ID NO:3)

-8-

Serial No.: 09/529,232

- 6) Bbs-Arg-(D-Pip)-Nle-Gly-Gly-Gly- β Ala-Asp-Tyr-Glu-Pro-Ile-Pro-Glu-Glu-Ala-Cha-(D-Glu)-OH;
(SEQ ID NO:3)
- 7) Bbs-Arg-(D-Pip)-Gly-Gly-(D-Nle)-Gly- β Ala-Asp-Tyr-Glu-Pro-Ile-Pro-Glu-Glu-Ala-Cha-(D-Glu)-OH;
(SEQ ID NO:3)
- 8) Bbs-Arg-(D-Pip)-Met-Gly-Gly-Gly- β Ala-Asp-Tyr-Glu-Pro-Ile-Pro-Glu-Glu-Ala-Cha-(D-Glu)-OH;
(SEQ ID NO:3)
- 9) Bbs-Arg-(D-Pip)-Val-Gly-Gly-Gly- β Ala-Asp-Tyr-Glu-Pro-Ile-Pro-Glu-Glu-Ala-Cha-(D-Glu)-OH;
(SEQ ID NO:3)
- 10) Bbs-Arg-(D-Pip)-Gly-Gly-(D-Val)-Gly- β Ala-Asp-Tyr-Glu-Pro-Ile-Pro-Glu-Glu-Ala-Cha-(D-Glu)-OH;
(SEQ ID NO:3)
- 11) Bbs-Arg-(D-Pip)-Gly-Gly-(D-Thg)-Gly- β Ala-Asp-Tyr-Glu-Pro-Ile-Pro-Glu-Glu-Ala-Cha-(D-Glu)-OH;
(SEQ ID NO:3)
- 12) Bbs-Arg-(D-Pip)-Ile-Gly-Gly-Gly- β Ala-Asp-Tyr-Glu-Pro-Ile-Pro-Glu-Glu-Ala-Cha-(D-Glu)-OH;
(SEQ ID NO:3)
- 13) Bbs-Arg-(D-Pip)-Gly-Gly-(D-Ile)-Gly- β Ala-Asp-Tyr-Glu-Pro-Ile-Pro-Glu-Glu-Ala-Cha-(D-Glu)-OH;
(SEQ ID NO:3)
- 14) Bbs-Arg-(D-Pip)-Lcu-Gly-Gly-Gly- β Ala-Asp-Tyr-Glu-Pro-Ile-Pro-Glu-Glu-Ala-Cha-(D-Glu)-OH;
(SEQ ID NO:3)
- 15) Bbs-Arg-(D-Pip)-Gly-Gly-(D-Lcu)-Gly- β Ala-Asp-Tyr-Glu-Pro-Ile-Pro-Glu-Glu-Ala-Cha-(D-Glu)-OH;

-9-

Serial No.: 09/529,232

(SEQ ID NO:3)

- 16) Bbs-Arg-(D-Pip)-Chg-Gly-Gly-Gly-βAla-Asp-Tyr-Glu-Pro-Ile-Pro-Glu-Glu-Ala-Cha-(D-Glu)-OH;

(SEQ ID NO:3)

- 17) Bbs-Arg-(D-Pip)-Cha-Gly-Gly-Gly-βAla-Asp-Tyr-Glu-Pro-Ile-Pro-Glu-Glu-Ala-Cha-(D-Glu)-OH;

(SEQ ID NO:3)

- 18) Bbs-Arg-(D-Pip)-Gly-Gly-(D-Phg)-Gly-βAla-Asp-Tyr-Glu-Pro-Ile-Pro-Glu-Glu-Ala-Cha-(D-Glu)-OH;

(SEQ ID NO:3)

- 19) Bbs-Arg-(D-Pip)-Phe-Gly-Gly-Gly-βAla-Asp-Tyr-Glu-Pro-Ile-Pro-Glu-Glu-Ala-Cha-(D-Glu)-OH;

(SEQ ID NO:3)

- 20) Bbs-Arg-(D-Pip)-Gly-Gly-(D-Phe)-Gly-βAla-Asp-Tyr-Glu-Pro-Ile-Pro-Glu-Glu-Ala-Cha-(D-Glu)-OH;

(SEQ ID NO:3)

- 21) Bbs-Arg-(D-Pip)-Hph-Gly-Gly-Gly-βAla-Asp-Tyr-Glu-Pro-Ile-Pro-Glu-Glu-Ala-Cha-(D-Glu)-OH;

(SEQ ID NO:3)

- 22) Bbs-Arg-(D-Pip)-Gly-Gly-(D-Hph)-Gly-βAla-Asp-Tyr-Glu-Pro-Ile-Pro-Glu-Glu-Ala-Cha-(D-Glu)-OH;

(SEQ ID NO:3)

- 23) Bbs-Arg-(D-Pip)-His-Gly-Gly-Gly-βAla-Asp-Tyr-Glu-Pro-Ile-Pro-Glu-Glu-Ala-Cha-(D-Glu)-OH;

(SEQ ID NO:3)

and

- 24) Bbs-Arg-(D-Pip)-Thi-Gly-Gly-Gly-βAla-Asp-Tyr-Glu-Pro-Ile-Pro-Glu-Glu-Ala-Cha-(D-Glu)-OH

(SEQ ID NO:3).

-10-

Serial No.: 09/529,232

Claim 6. (currently amended) The inhibitor of claim 1, wherein said inhibitor is selected from the group consisting of:

Supprimé : compound

Supprimé : compound

- 1) Bbs-Arg-(D-Pip)-Nle-Gly-Gly-Gly-βAla-Asp-Tyr-Glu-Pro-Ile-Pro-Glu-Glu-Ala-Cha-(D-Glu)-OH;

(SEQ ID NO:3)

- 2) Bbs-Arg-(D-Pip)-Gly-Gly-(D-Phg)-Gly-βAla-Asp-Tyr-Glu-Pro-Ile-Pro-Glu-Glu-Ala-Cha-(D-Glu)-OH;

(SEQ ID NO:3)

and

- 3) Bbs-Arg-(D-Pip)-Thi-Gly-Gly-Gly-βAla-Asp-Tyr-Glu-Pro-Ile-Pro-Glu-Glu-Ala-Cha-(D-Glu)-OH

(SEQ ID NO:3).

Claim 7. (Deleted)

Claim 8. (Deleted)

Claim 9. (currently amended) A pharmaceutical composition for treating vascular disease, said composition comprising a therapeutically effective amount of an inhibitor as defined in claim 1, and a pharmaceutically acceptable carrier.

Supprimé : or preventing

Supprimé : a compound

Claim 10. (currently amended) A pharmaceutically acceptable composition for treating vascular disease in a mammal, comprising an inhibitor as defined in claim 1, a thrombolytic agent and a pharmaceutically acceptable carrier.

Supprimé : combination

Supprimé : or preventing

Supprimé : a compound

Claim 11. (Currently amended) The composition according to claim 10, wherein said thrombolytic agent is tissue plasminogen activator.

Supprimé : combination

Claim 12. (Currently amended) The composition according to claim 10, wherein said mammal is a human.

Supprimé : combination

-11-

Serial No.: 09/529,232

Claim 13. (Currently amended) A method for the treatment of vascular diseases of a mammal comprising the administration of an effective amount of a composition according to claim 10.

Supprimé : or prevention

Claim 14. (Original) The method according to claim 13, wherein said mammal is a human.